Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG4050 in high grade serous carcinoma
NCT03839524Phase 1Completed
- Sponsor
- Transgene SA
- Start
- Dec 2019
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of TG4050 in ovarian carcinoma, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Transgene SA. Primary endpoint: Adverse Events at 1 year. Started Dec 2019; status: completed.
02
Drugs
TG4050
03
Conditions
ovarian carcinomafallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03839524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839524.